Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacubitril/Allisartan and Amlodipine in Uncontrolled Essential Hypertension
NCT07704697Phase 3Completed
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
- Start
- Nov 2024
- Primary completion
- Nov 2025
- Countries
- 1
01
Overview
A Phase 3 trial of sacubitril + valsartan, amlodipine in essential hypertension, sponsored by Shenzhen Salubris Pharmaceuticals Co., Ltd.. Started Nov 2024; status: completed.
02
Drugs
sacubitril + valsartanamlodipine
03
Conditions
essential hypertension
Beyond the preview
Go deeper on NCT07704697.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07704697.